BTAI: BioXcel Therapeutics, Inc. Common Stock Company Profile & Statistics

About

BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States.

Info & Links

CEO

Vimal Mehta

Headquarters

555 LONG WHARF DRIVE
NEW HAVEN, CT 06511, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

BioXcel Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

10.13M

Enterprise Value

74.18M

Enterprise Value/EBITDA(ttm)

-0.97

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

3.13

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

-98.28%

Operating Margin(ttm)

-3119.33%

Profit Margin(ttm)

-3675.11%

Return on Equity(ttm)

Return on Invested Capital(ttm)

-308.46%

Return on Assets(ttm)

-105.04%

Income Statement

Revenue(ttm)

2.28M

Revenue Per Share(ttm)

0.85

Gross Profit(ttm)

251.00K

EBITDA(ttm)³

-76.31M

Net Income Available to Common(ttm)

-71.00M

Diluted EPS(ttm)

-34.56

Share Statistics

Beta (5Y Monthly)

-0.01

52-Week Change

-95.70%

S&P 500 52-Week Change

3.55%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

2.67M

Dividend Yield

0.00%

Float⁴

2.44M

% Held by Insiders

21.20%

% Held by Institutions

30.68%

Balance Sheet

Total Cash(mrq)

40.39M

Total Cash Per Share(mrq)

15.12

Total Debt(mrq)

104.44M

Total Debt/Equity(mrq)

-110.10%

Current Ratio(mrq)

1.68%

Quick Ratio(mrq)

1.81%

Book Value Per Share(mrq)

-30.01

Cash Flow

Operating Cash Flow Per Share(ytd)

-28.41

Free Cash Flow(ytd)

-72.03M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

BTAI

BioXcel Therapeutics, Inc. Common Stock

BioXcel Therapeutics, Inc. Common Stock Profile